Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto

[1]  M. Rezai,et al.  Abstract P1-17-01: Development of brain metastases in breast cancer patients treated in the neoadjuvant trials Geparquinto and Geparsixto , 2018 .

[2]  K. Hunt,et al.  Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance) , 2017, Annals of surgery.

[3]  P. Wen,et al.  Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study , 2017, JAMA oncology.

[4]  W. Weichert,et al.  10PComparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls , 2017 .

[5]  A. Schneeweiss,et al.  Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Z. Ren,et al.  Breast cancer subtypes predispose the site of distant metastases. , 2015, American journal of clinical pathology.

[7]  M. Rezai,et al.  Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  H. Iwata,et al.  Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis , 2014, Breast Cancer Research and Treatment.

[9]  M. Rezai,et al.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[10]  A. Giobbie-Hurder,et al.  Challenges of guarantee-time bias. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Rezai,et al.  Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). , 2013, European journal of cancer.

[12]  L. Tanoue,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[13]  S. Bhatia,et al.  The shifting landscape of metastatic breast cancer to the CNS , 2013, Neurosurgical Review.

[14]  E. Winer,et al.  Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network , 2012, Cancer.

[15]  G. Hortobagyi,et al.  Incidence of brain metastases as a first site of recurrence among women with triple receptor–negative breast cancer , 2012, Cancer.

[16]  J. Niland,et al.  Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study , 2012, Breast Cancer Research.

[17]  A. Niemierko,et al.  Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype , 2012, Breast Cancer Research and Treatment.

[18]  M. Rezai,et al.  Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. , 2012, The Lancet. Oncology.

[19]  V. Kataja,et al.  Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study , 2011, Breast Cancer Research.

[20]  G. Hortobagyi,et al.  Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Pogoda,et al.  Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[24]  M. Hayran,et al.  Percent Positive Axillary Involvement Predicts for the Development of Brain Metastasis in High‐Risk Patients with Nonmetastatic Breast Cancer Receiving Post‐Mastectomy Radiotherapy , 2008, The breast journal.

[25]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.

[26]  G. Hortobagyi,et al.  Central nervous system metastases in patients with high‐risk breast carcinoma after multimodality treatment , 2004, Cancer.

[27]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .